Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects

Journal of Clinical Pharmacology

Volumn 55, Issue 9, 2015, Pages 1024-1030

  Bui, Khanh H ^a   Zhou, Diansong ^a   Agbo, Felix ^a   Guo, Jian ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

drug drug interaction; lanicemine; midazolam

Indexed keywords

CYTOCHROME P450 3A; LANICEMINE; MIDAZOLAM; ANTIDEPRESSANT AGENT; CENTRAL DEPRESSANT AGENT; PHENETHYLAMINE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; COMPUTER MODEL; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EUPHORIA; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; NEUROLOGIC DISEASE; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; YOUNG ADULT;

ADJUVANTS, ANESTHESIA; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDAZOLAM; MIDDLE AGED; PHENETHYLAMINES; PYRIDINES; YOUNG ADULT;

EID: 84937685629     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.515     Document Type: Article

References (18)

1. Sanacora G, Smith MA, Pathak S, et al., Lanicemine: a low-trapping NMDA channel blocker producessustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014; 19: 978-985.
2. Zarate CA Jr, Mathews D, Ibrahim L, et al., A randomized trial of a low-trapping nonselectiveN-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry. 2013; 74 (4): 257-264.
3. Dolgin E., Rapid antidepressant effects of ketamine ignite drug discovery. Nat Med. 2013; 19 (1): 8.
4. Sanacora G, Johnson M, A Khan A, et al., Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and a history of inadequate response to antidepressants: primary results from a randomized, placebo-controlled study (PURSUIT). Poster presented at: 2014 Annual Meeting of the American Society of Clinical Pharmacology (NCDEU); June 16-19, 2014; Hollywood, FL. Poster 54. http://ascpmeeting.org/wp-content/uploads/2014/06/Poster-Abstracts-FINAL.pdf.
5. McCarthy DJ, Alexander R, Smith MA, et al., Glutamate-based depression GBD. Med Hypotheses. 2012; 78 (5): 675-681.
6. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr,. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther. 2009; 123: 143-150.
7. Autry AE, Adachi M, Nosyreva E, et al., NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011; 475: 91-95.
8. Krystal JH, Karper LP, Seibyl JP, et al., Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994; 51: 199-214.
9. Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA Jr,. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry. 2008; 69: 946-958.
10. Guo J, Zhou D, Grimm SW, Bui KH,. Pharmacokinetics, metabolism and excretion of [(14)C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects. Xenobiotica. 2015; 45 (3): 244-255.
11. Zhao P, Zhang L, Grillo JA, et al., Applications of physiologically based pharmacokinetic (PBPK) modelling and simulation during regulatory review. Clin Pharmacol Ther. 2011; 89: 259-267.
12. Darwish M, Kirby M, Robertson P Jr, Hellriegel ET,. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008; 47 (1): 61-74.
13. Karalis V, Macheras P, Symillides M., Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties. Eur J Pharm Sci. 2005; 26 (1): 54-61.
14. Knoester PD, Jonker DM, van der Hoeven RTM, et al., Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol. 2002; 53 (5): 501-507.
15. Heizmann P, Eckert M, Ziegler WH,. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol. 1983; 16: 43S-49S.
16. US Food and Drug Administration. Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf. Accessed August 6, 2014.
17. Yeo KR, Jamei M, Rostami-Hodjegan A., Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Rev Clin Pharmacol. 2013; 6: 143-157.
18. Jones HM, Dickins M, Youdim K, et al., Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica. 2012; 42: 94-106.